This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Sagent Pharmaceuticals Named To Crain's Chicago Business 2014 Fast Fifty List

Stocks in this article: SGNT

SCHAUMBURG, Ill., June 9, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leading specialty pharmaceutical company with an emphasis on the injectable market, has been ranked seventh on Crain's 2014 Fast Fifty list, published by Crain's Chicago Business. This marks the second consecutive year that Sagent has been selected as one of the leading growth companies in Chicago, topping the charts as number one in 2013. The Crain's Fast Fifty is an annual ranking that features the fastest-growing companies in Chicago.

"We are honored to be ranked among an elite group of our peers in the Chicago area. This recognition is a true testament to the proven success of our business which has enabled rapid and consistent revenue growth and has distinguished the company as a leader in Chicago," said Jeffrey Yordon, Chairman and Chief Executive Officer of Sagent Pharmaceuticals, Inc. "Our focus remains on identifying new ways to increase the breadth of our product portfolio and opportunities to innovate within the generic pharmaceutical industry. We attribute a great deal of our success to the collaborative efforts of our partners around the world, as well as to our employees' ongoing focus and commitment to the patients we serve."

As one of the fastest-growing providers of generic injectables in the U.S. market, Sagent Pharmaceuticals has a highly unique business model that combines best-in-class quality and service, an extensive global network of partners with state-of-the-art technology, and global excellence in manufacturing– including its own development and manufacturing facility in Chengdu, China. As part of its innovative approach to packaging and labeling, Sagent's PreventIV Measures SM Packaging and Labeling helps to make accurate medication selection an easy and obvious choice for caregivers. Sagent's unmatched expertise and industry-leading resources enables the company to direct and scale resources to anticipate and rapidly meet customer needs.

The Crain's Fast Fifty list is an annual index of Chicago-based businesses, ranked by revenue growth over the recent five year period. Fast Fifty companies span all industries, sizes and operating models. Crain's editorial staff is responsible for determining the contents of this ranking. The 2014 Fast Fifty rankings were announced in the June 2 issue of Crain's Chicago Business. A breakfast will be held on Thursday, June 26, at the Four Seasons Hotel in Chicago, in honor of this year's top companies.

To learn more about Sagent and to view the full 2014 Crain's Fast Fifty list, visit: www.chicagobusiness.com/fastfifty .

About Sagent Pharmaceuticals

Sagent Pharmaceuticals, Inc., founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

CONTACT: MEDIA CONTACT:
         Irma Gomez-Dib
         irma.gomez-dib@fticonsulting.com
         (212) 850-5761
         
         INVESTOR CONTACT:
         Jonathon Singer
         jsinger@sagentpharma.com
         (847) 908-1605

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs